Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
Haematologica
Allan, John N JN; Pinilla-Ibarz, Javier J; Gladstone, Douglas E DE; Patel, Krish K; Sharman, Jeff P JP; Wierda, William G WG; Choi, Michael Y MY; O'Brien, Susan M SM; Shadman, Mazyar M; Davids, Matthew S MS; Pagel, John M JM; Yimer, Habte A HA; Ward, Renee R; Acton, Gary G; Taverna, Pietro P; Combs, Daniel L DL; Fox, Judith A JA; Furman, Richard R RR; Brown, Jennifer R JR